Re-salvage MRI-guided Focal High-dose-rate Brachytherapy for Locally Recurrent Prostate Cancer

Prostate cancer recurrences are common, even with twenty-first-century primary prostate cancer treatment modalities. The most common salvage treatment is (delayed) hormonal therapy, which is often associated with serious side-effects. Due to the risk of significant toxicity, whole-gland targeted sal...

Descripción completa

Detalles Bibliográficos
Autores principales: Van Son, Marieke J, Peters, Max, Moerland, Marinus A, Noteboom, Juus L, Eppinga, Wietse S, Davila Fajardo, Raquel, Lagendijk, Jan, Van der Voort van Zyp, Jochem R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2018
Materias:
Medical Physics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5988341/
https://www.ncbi.nlm.nih.gov/pubmed/29876151
http://dx.doi.org/10.7759/cureus.2429
Descripción
Sumario:Prostate cancer recurrences are common, even with twenty-first-century primary prostate cancer treatment modalities. The most common salvage treatment is (delayed) hormonal therapy, which is often associated with serious side-effects. Due to the risk of significant toxicity, whole-gland targeted salvage treatments remain unpopular. Consequently, developments in focal therapies have arisen. Magnetic resonance imaging (MRI)-guided focal salvage high-dose-rate brachytherapy (HDR-BT) is a novel treatment aiming for minimal toxicity in recurrent prostate cancer patients. Repeating focal treatment could, therefore, be possible in case of post-salvage recurrence. We report the case of a 77-year-old man who underwent repeat focal HDR-BT.

Ejemplares similares